COVID-19

Quantitative COVID-19 Serology Testing to Measure Immune Response


ProterixBio offers the quantitative COVID-19 serology testing services through our high-complexity, CLIA-certified clinical testing laboratory. Our lead test measures antibodies that bind the Receptor Binding Domain (RBD) of the spike protein of the SARS-CoV-2 virus, which are associated with neutralizing activity and relevant to potential development of immunity. The test output is a numerical index related to the levels of antibodies and can be tracked over time.

Learn more about how ProterixBio’s quantitative COVID-19 serology test fits into vaccination follow up.

View our COVID-19 Serology Test Menu

Quantitative Serology Testing Can Better Assess Immune Response Following SARS-CoV-2 Vaccination

The novel nature of SARS-CoV-2 and our limited experience with newly developed vaccines motivates the inclusion of immune status monitoring in the design of vaccination programs. Quantitative COVID-19 serology tests that measure levels of antibodies associated with neutralizing antibodies can be used to assess immune response and durability over time.

Learn more by reading:

Quantitative Serology Testing Can Better Assess Immune Response Following SARS-CoV-2 Vaccination

.

Serology Testing Plays an Important Role in the Management of COVID-19

Measuring immune response through antibody levels, especially antibodies associated with neutralizing activity, is an important part of managing COVID-19. Critical applications include:

Assess an individual’s
immune response to
vaccination.

Determine prior exposure to SARS-CoV-2, confirm cases that were missed by PCR or antigen tests.

Track antibody levels after
vaccination
or infection and
assess durability.

Identify asymptomatic
cases
and potential
transmission paths.

Measure the overall
prevalence of COVID-19

in an organization or community.

About ProterixBio

ProterixBio is a high-complexity, CLIA-certified clinical testing laboratory that develops and commercializes diagnostic solutions that address critical unmet needs in population health and chronic care. An area of focus has been vulnerable populations such as those with chronic obstructive pulmonary disease, diabetes and cardiovascular disease. The company has developed algorithms utilizing combinations of blood-based biomarkers for identifying individuals at high risk for severe outcomes. ProterixBio maintains a rigorous approach to test development that includes collaborating with leading academic medical centers and validating assays in large, carefully curated cohorts. ProterixBio is headquartered in Billerica, MA.

Contact Us
Follow Us on LinkedIn

Latest Updates

Press Releases View All

For more information: